Evidence map›Paper›PMID 29785462›Full record

ArticleInternational journal of colorectal disease2018

The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.

Ann Christina Eriksen, Flemming B Sørensen, Jan Lindebjerg, Henrik Hager, René dePont Christensen, Sanne Kjær-Frifeldt, Torben F Hansen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of colorectal disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. A high tumour-stroma ratio (TSR) in colon tumours and its metastatic lymph nodes predicts poor cancer-free survival and chemo resistance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ann Christina EriksenDanish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark. ann.christina.eriksen@rsyd.dk.ORCID http://orcid.org/0000-0002-3905-4132
Flemming B SørensenDanish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark.
Jan LindebjergDanish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark.
Henrik HagerDanish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark.
René dePont ChristensenResearch Unit of General Practice, University of Southern Denmark, Odense, Denmark.
Sanne Kjær-FrifeldtDanish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark.
Torben F HansenDanish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark.

Funding

The Danish Cancer Research Foundation. 127.000The Research Council of Lillebaelt Hospital 50.000
6 · The paper itself

Abstract

purposeHigh-risk patients with stage II colon cancer (CC) may benefit from adjuvant chemotherapy, but additional prognostic markers are needed for better stratification. We investigated the prognostic value of tumour stroma ratio (TSR) and tumour budding (TB).

methodsA nationwide population-based cohort of 573 patients with stage II CC was included. TSR was scored on hematoxylin and eosin sections as low TSR (> 50% stroma) and high TSR (≤ 50% stroma). TB was evaluated in hotspots on pan-cytokeratin stained sections in 10 high power fields (HPF) at the invasive front and classified by the mean number of buds per HPF as high grade budding (≥ 10 buds) or low-grade budding (< 10 buds). The prognostic value was investigated in Cox proportional hazard models for recurrence-free survival (RFS) and overall survival (OS).

resultsLow TSR was associated with worse RFS (HR = 1.342 (95% CI 1.006-1.791), p = 0.045) and OS (HR = 1.376 (95% CI 1.016-1.862), p = 0.039). Furthermore, an association was found between low TSR and microsatellite stabile tumours (p < 0.001). The mean number of buds per HPF was associated to TSR with increasing number of buds related to a lower TSR (p = 0.026). No statistically significant prognostic impact of TB regarding OS or RFS was detected.

conclusionsTSR provided valuable prognostic information, and adding TSR to the current risk stratification may contribute to better patient selection. The estimates of TSR and TB were found to be associated, but no prognostic value of TB was documented.

Indexed as

Neoplasm StagingAdultAgedChildChild, PreschoolColonic NeoplasmsDenmarkFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesColon cancer stage IIPrognostic markersSurvivalTumour buddingTumour stroma ratio

Identifiers

PMID29785462
PMCPMC6060800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.